Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S225500, C514S277000, C514S469000, C514S588000, C514S595000
Reexamination Certificate
active
07875632
ABSTRACT:
Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions.
REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4353901 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4401665 (1983-08-01), Sheinaus et al.
patent: 4853394 (1989-08-01), King et al.
patent: 4908369 (1990-03-01), Schechter et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214044 (1993-05-01), Cooper et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5874445 (1999-02-01), Carr et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5952324 (1999-09-01), Barbachyn et al.
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6479480 (2002-11-01), Moyes et al.
patent: 6486153 (2002-11-01), Pineiro et al.
patent: 6617339 (2003-09-01), Gravestock
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 7253186 (2007-08-01), Andersson et al.
patent: 7601740 (2009-10-01), Weiner et al.
patent: 2002/0004513 (2002-01-01), Andersson et al.
patent: 2002/0035145 (2002-03-01), Tsai et al.
patent: 2002/0156068 (2002-10-01), Behan et al.
patent: 2002/0165225 (2002-11-01), Hamied et al.
patent: 2003/0092700 (2003-05-01), Czollner et al.
patent: 2003/0220316 (2003-11-01), Andersson et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0111399 (2006-05-01), Thygesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0194834 (2006-08-01), Andersson et al.
patent: 2006/0199794 (2006-09-01), Schlienger
patent: 2006/0199818 (2006-09-01), Andersson et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0205710 (2006-09-01), Schlienger et al.
patent: 2006/0205722 (2006-09-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thygesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2006/0286610 (2006-12-01), Brann
patent: 2006/0292606 (2006-12-01), Brann
patent: 984843 (1976-03-01), None
patent: 0 005 318 (1979-11-01), None
patent: 0 056 144 (1982-07-01), None
patent: 0 061 333 (1982-09-01), None
patent: 0 379 441 (1990-07-01), None
patent: 0 548 015 (1993-06-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0 625 507 (1994-11-01), None
patent: 1 656 938 (2006-05-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: 51052176 (1976-05-01), None
patent: 5208517 (1977-05-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/17646 (1998-04-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 02/24649 (2002-03-01), None
patent: WO 02/076464 (2002-10-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/009549 (2004-01-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/072034 (2004-08-01), None
patent: WO 2005/042502 (2005-05-01), None
patent: WO 2005/053796 (2005-06-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO 2005/115361 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
patent: WO 2006/104826 (2006-10-01), None
patent: WO 2004/039322 (2007-05-01), None
Acadia Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis Acadia Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis, Press Release (Business Wire, San Diego), Sep. 1, 2009.
Acadia Pharmaceuticals Provide Update on Pimavanserin Collaborative Development Program, Press Release (Business Wire, San Diego), Oct. 6, 2009.
Adam, et al. “Effects of repeated ritanserin on middle-aged poor sleepers,” Psychopharmacology, 99:219-221 (1989).
Adell, et al., “Strategies for producing faster acting antidepressants,” Drug Discovery Today, 10(8):578-585 (2005).
Akin, et al., “Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients,” Neuropsychopharmacology, 29:2081-2087 (2004).
Alvisi, “Sulla formazione di derivati pirazolici dalle didoridrine e dalla tribromidrina della glicerina ordinaria,” Gazz. Chem. Ital. 22:158-168 (1892).
Antilla, at al., “Copper-catalyzed coupling of arylboronic acids and amines,” Organic Letters, 3(13):20n-2079 (2001).
Antilla, et al., “The copper-catalyzed N-arylation of indoles,” J. Am. Chern. Soc., 124:11684-11688 (2002).
Archibald et al., “Benzamidopiperdines. 3. Heterocydic Compounds Related to Indoramin,” J. Medicinal Chemistry, 17(7):-739-744 (1974).
Archibald et al., “1,4-Bis-(2-indol-3-ylethyl)piperdines,” J. Medicinal Chemistry, 17(7):-745-747 (1974).
Archibald, et al., “Benzamidopiperdines. 2. Heterocydic Compounds Related to Indoramin,” J. Medicinal Chemistry, 17(7):736-739 (1974).
Artico et al., “Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase,” Eur. J. Med. Chern., 27:219-228 (1992).
Avemaria et al., “Sythesis of aryl azides via post-cleavage modifications of polymer-bound triazenes,” Synlett 7:1163-1166 (2004).
Bakshi et al., “Clozapine antagonizes phencydidine-induced deficits in sensorimotor gating of the startle response,” The Journal of Pharmacology and Experimental Therapeutics, 271(2):787-794 (1994).
Barchas et al., Serotonin and behavior, pp. 483-498, 523-560 (1973), NY: Academic Press.
Barnes et al., “A review of central 5-HT receptors and their function,” Neuropharmacology, 38: 1083-1152 (1999).
Barr et al., “Agonist-independent activation of Gz by the 5-hydroxytryptamine1Areceptor co-expressed in Spodootera frugiperda cells,” The Journal of Biological Chemistry, 272(52):32979-32987 (1997).
Bassus et al., “Psychotropes potentiels. X. Synthese de butyroph
Brann Mark R.
Davis Robert E.
Weiner David M.
Acadia Pharmaceuticals Inc.
Javanmard Sahar
Jones Day
Padmanabhan Sreeni
LandOfFree
Selective serotonin receptor inverse agonists as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective serotonin receptor inverse agonists as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective serotonin receptor inverse agonists as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2685634